David J. Chaplin

9.8k citations

157 papers · 8.3k indexed · h-index 51

Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism 55
- Protease and Inhibitor Mechanisms 10
Oncology top 1%
- Cancer Treatment and Pharmacology 11
Biotechnology top 0.5%
Radiology, Nuclear Medicine and Imaging top 1%
Molecular Biology top 2%
- Angiogenesis and VEGF in Cancer 38
Organic Chemistry
- Synthesis and biological activity 17
Biomedical Engineering
- Nanoplatforms for cancer theranostics 10
Pulmonary and Respiratory Medicine
- Radiation Therapy and Dosimetry 10
Physiology
- Nitric Oxide and Endothelin Effects 9

Co-authors: Michael R. Horsman Peggy L. Olive Dietmar W. Siemann Sally A. Hill Ralph E. Durand Gillian M. Tozer George R. Pettit Scott L. Young
Cited by: Cancer Research Oncology Biotechnology
Journals: International Journal of Radiation Oncology*Biology*Physics (23 papers)Radiotherapy and Oncology (10 papers)British Journal of Cancer (7 papers)
Partner nations: United Kingdom United States Canada

In The Last Decade

David J. Chaplin

155 papers receiving 8.0k citations

Peers

Countries citing papers authored by David J. Chaplin

Since Specialization

Citations

This map shows the geographic impact of David J. Chaplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Chaplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Chaplin more than expected).

Fields of papers citing papers by David J. Chaplin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. Chaplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Chaplin. The network helps show where David J. Chaplin may publish in the future.

Co-authorship network

The 25 scholars most cited alongside David J. Chaplin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David J. Chaplin Line = papers co-authored together David J. Chaplin links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia Bioorganic & Medicinal Chemistry Letters ·Hiram Yeakel,Zhe Shi,Bolívar Ana María,Yifan Wang,CHOU ER,Qi Dong,Ayuningtyas Nadya,Ernest Hamel,David J. Chaplin,Mary Lynn Trawick,Kevin G. Pinney	2016	16
2	Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks Bioorganic & Medicinal Chemistry Letters ·Chol Lee,Lindsay M. Jones,Hyoungkeun Park,Yongbin Jiang,Paulus LEOPARDUS,A. Myagkov,Liela Bayeh,Mathilde Cléman,rochelle claire Barclay,K Tielking,David J. Chaplin,Mary Lynn Trawick,Kevin G. Pinney	2012	20
3	A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer British Journal of Cancer ·Gordon Rustin,Kathryn Greenleaf ARNP,Paul Nathan,Andrew Gaya,Trivadi S. Ganesan,Mirja Kostekivi-Ohenoja,J Boxall,Anisah Fitriani,David J. Chaplin,M.R.L. Stratford,Jai Balkissoon,Martin Zweifel	2010	116
4	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors Bioorganic & Medicinal Chemistry Letters ·G.D. Kishore Kumar,Hyoungkeun Park,Yongbin Jiang,Ana Aguinaga-Barrilero,Chang-Tse Lu,Tracy E. Strecker,Shen-En Chen,Bronwyn G. Siim,David J. Chaplin,Mary Lynn Trawick,Kevin G. Pinney	2010	37
5	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents Cancer Research ·Yuval Shaked,Terence Tang,Jill Woloszynek,Laura G.M. Daenen,Shan Man,Ping Xu,Shi-Rong Cai,Jeffrey M. Arbeit,Emile E. Voest,David J. Chaplin,Jon Smythe,Adrian L. Harris,Paul Nathan,Ian Judson,Gordon Rustin,Francesco Bertolini,Daniel C. Link,Robert S. Kerbel	2009	64
6	Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4 Bioorganic & Medicinal Chemistry Letters ·SS Shinde,Amit Tolani,Tracy E. Strecker,陈飞 CHEN Fei,Danladi Austine Markus,G.D. Kishore Kumar,Mallinath B. Hadimani,George R. Pettit,David J. Chaplin,Mary Lynn Trawick,Kevin G. Pinney	2008	19
7	An update on the clinical development of drugs to disable tumor vasculature Expert Opinion on Drug Discovery ·Dietmar W. Siemann,David J. Chaplin	2007	11
8	Combretastatin A4 phosphate: background and current clinical status Expert Opinion on Investigational Drugs ·Scott L. Young,David J. Chaplin	2004	163
9	ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Oxford University Research Archive (ORA) (University of Oxford) ·Peter D. Davis,Graeme J. Dougherty,David C. Blakey,Susan Galbraith,Gillian M. Tozer,Angela Holder,Matthew A. Naylor,John Nolan,Michael R.L. Stratford,David J. Chaplin,Sally A. Hill	2002	200
10	Tumour Radiosensitization by High-Oxygen–Content Gases: Influence of the Carbon Dioxide Content of the Inspired Gas on pO2, Microcirculatory Function and Radiosensitivity International Journal of Radiation OncologyBiologyPhysics ·Sally A. Hill,A.H. Ball,Borivoj Vojnovic,David J. Chaplin	1998	49
11	The comparative effects of the NOS inhibitor, nω-nitro-l-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow International Journal of Radiation OncologyBiologyPhysics ·Gillian M. Tozer,Vivien E. Prise,Roberto Motterlini,Brennan Collis,John Wilson,David J. Chaplin	1998	21
12	Vascular response of tumour and normal tissues to endothelin-1 following antagonism of ETA and ETB receptors in anaesthetised rats International Journal of Cancer ·Katrina M. Bell,Vivien E. Prise,David J. Chaplin,Michele Oskarina,Gillian M. Tozer	1997	8
13	Nicotinamide reduces tumour interstitial fluid pressure in a dose- and time-dependent manner. British Journal of Radiology ·Ya Di,David J. Chaplin,D G Hirst	1997	10
14	Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry Radiotherapy and Oncology ·K. Pigott,Stephen Hill,David J. Chaplin,M.I. Saunders	1996	71
15	The Ability of Nicotinamide to Inhibit the Growth of a C3H Mouse Mammary Carcinoma Acta Oncologica ·Michael R. Horsman,Azza A. Khalil,David J. Chaplin,Jens Overgaard	1995	8
16	Biological Effectiveness of Fractionated Dose of Pions in Microscopic SCCVII Tumors: Comparison between Tumor Control Dose and Tumor Growth Time Assays Japanese Journal of Cancer Research ·王立芝,Gabriel K. Y. Lam,Tom Pickles,David J. Chaplin	1995	1
17	The Combination of Nicotinamide and Carbogen Breathing to Improve Tumour Oxygenation Prior to Radiation Treatment Advances in experimental medicine and biology ·Michael R. Horsman,Dietmar W. Siemann,Marianne Nordsmark,Azza A. Khalil,Jens Overgaard,David J. Chaplin	1994	14
18	The effect of hypoxia and low pH on the cytotoxicity of chlorambucil International Journal of Radiation OncologyBiologyPhysics ·L. D. Skarsgard,David J. Chaplin,Douglas J. Wilson,Jesús Insúa Pohls,John Stakely Keller,Yuting Zhao	1992	13
19	The use of fluorescent probes to identify regions of transient perfusion in murine tumors International Journal of Radiation OncologyBiologyPhysics ·Martin J. Trotter,David J. Chaplin,Ralph E. Durand,Peggy L. Olive	1989	147
20	Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs International Journal of Radiation OncologyBiologyPhysics ·David J. Chaplin,Brian D. Acker,Peggy L. Olive	1989	37

About David J. Chaplin

David J. Chaplin is a scholar working on Cancer Research, Toxicology, Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 157 papers that have together received 8.3k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (55 papers), Angiogenesis and VEGF in Cancer (38 papers), Synthesis and biological activity (17 papers), Cancer Treatment and Pharmacology (11 papers), Protease and Inhibitor Mechanisms (10 papers), Nanoplatforms for cancer theranostics (10 papers), Radiation Therapy and Dosimetry (10 papers) and Nitric Oxide and Endothelin Effects (9 papers). The work is most often cited by research in Cancer Research (3.0k citations), Oncology (1.9k citations), Biotechnology (556 citations), Radiology, Nuclear Medicine and Imaging (1.3k citations) and Molecular Biology (3.8k citations). David J. Chaplin has collaborated with scholars based in United Kingdom, United States and Canada. Frequent co-authors include Michael R. Horsman, Peggy L. Olive, Dietmar W. Siemann, Sally A. Hill, Ralph E. Durand, Gillian M. Tozer, George R. Pettit, Scott L. Young, Borivoj Vojnovic and M.R.L. Stratford. Their work appears in journals such as International Journal of Radiation Oncology*Biology*Physics, Radiotherapy and Oncology, British Journal of Cancer, Bioorganic & Medicinal Chemistry Letters and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact